Skip To Main Content
John Strickler on Muck Rack

John Strickler

Pennsylvania
As seen in: Nature, MDPI, Taylor & Francis Online, JAMA Oncology, Medscape, The New England Journal of Medicine, The Lancet, Cell Press, HemOnc Today, Healio and
John Strickler is photography supervisor at the @MercuryX newspaper in Pottstown,Pa. Enjoys hiking, traveling and fly fishing.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis

|
By Binbin Zheng-Lin, Taro Shibuki, Heidi E. Kosiorek, Oluseyi Abidoye, Cody Eslinger, Yasuyuki Kawamoto, Ryne C. Ramaker, Shinji Itoh, Tadayoshi Hashimoto, Takao Fujisawa, Mitsuho Imai, Angelo Pirozzi, Celine Hoyek, Mohamad B. Sonbol, Christina Wu, Nguyen Tran, Hani M Babiker, Lewis Roberts, Ashley Moyer, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Makoto Ueno, Chigusa Morizane, Daniel Ahn, Mitesh J. Borad, John Strickler, Masafumi Ikeda, Tanios S Bekaii-Saab, Madhuri Gottam
| Nature Verified
Abstract The prognosis of advanced biliary tract cancer remains poor despite up to 40% of tumors harboring actionable molecular alterations. This international collaborative study from Mayo Clinic, Duke Cancer Institute, National Cancer Center East (Japan), and the SCRUM-Japan GOZILA/MONSTAR-SCREEN projects evaluated clinical outcomes in 1049 patients with advanced BTC based on tumor molecular profiling and matched treatment selection.
Open in Who Shared Issue with article?

Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients

|
By Andrew Nixon Verified, Fabio Navarro, Katherine Zhou, Charles Abbott, Lee McDaniel, Lauren Howard, J. Brady, Donna Niedzwiecki, John Strickler, Sean Boyle, Richard Chen, Hope E. Uronis, Neeraja Ravi, Yingmiao Liu, Jingquan Jia
| Nature Verified
Abstract To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab.
Open in Who Shared Issue with article?

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis - Nature Communications

|
By John Strickler, Salvatore Siena, Thierry Andre, Thierry André, Kimmie Ng, Christos Fountzilas, Pashtoon Murtaza Kasi, Heinz-Josef Lenz, Elena Elez, Chiara Cremolini
| Nature Verified
Abstract MOUNTAINEER was a multicenter, open-label, phase 2 trial (NCT03043313) that evaluated the efficacy and safety of tucatinib plus trastuzumab, a dual HER2-targeted chemotherapy-free regimen. Patients were included if they had chemotherapy-refractory, HER2+, RAS wild-type unresectable or metastatic colorectal cancer. This final analysis reports updated efficacy and safety after a median follow-up of 32.4 months.
Open in Who Shared Issue with article?
See all 82 licensed articles (128 Total)